Mirosamicin

This classification denotes a macrolide antibiotic with the molecular formula C37H61NO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K7G02HKM1X, chemically known as 4,17-dioxabicyclo(14.1.0)heptadeca-6,14-diene-5,13-dione, 2-(((6-deoxy-2,3-di-o-methyl-beta-d-allopyranosyl)oxy)methyl)-3-ethyl-2-hydroxy-8,10,12-trimethyl-9-((3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl)oxy)-, (1r,2s,3r,6e,8s,9s,10s,12r,14e,16s)- but generally known as mirosamicin, which bears US NIH Compound Identifier 6436150. European Medicines Agency schedules Mirosamicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08995MIG. The term MIROSAMICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). MIROSAMICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mirosamicin under HS 29419000 and SITC 54139. As of Q4 2014, MIROSAMICIN remains the US FDA Preferred Term for this commodity. Mirosamicin bears US NLM identifiers UMLS ID C0245985 and NCI Concept Code C90878. SMILES: O1C2C(O)(C(OC(=O)C=CC(C(OC3OC(CC(N(C)C)C3O)C)C(CC(C(=O)C=CC12)C)C)C)CC)COC1OC(C(O)C(OC)C1OC)C.